(Registrieren)

RHEI Pharmaceuticals and Drs. Hans Schreuder Products Enter Into Licensing Agreement Surrounding Line of Natural Skin Care Products

Geschrieben am 21-02-2008

New Haven, Connecticut, and Netherlands (ots/PRNewswire) -

- RHEI to Market and Distribute Drs. Hans Schreuder Vision for
Health Skin Care Line Throughout Asia -

RHEI Pharmaceuticals, Inc., a fully integrated specialty
pharmaceuticals company focused on bringing proprietary medicines to
the China market, and Drs. Hans Schreuder Products BV today announced
that RHEI has licensed from Drs. Hans Schreuder Products the
exclusive right to market and distribute the Drs. Hans Schreuder
Vision for Health Skin Care line throughout Asia. The natural skin
care line will be marketed through RHEI's Pharmacy Division which
focuses on consumer healthcare and neutraceuticals.

"Drs. Hans Schreuder natural skin care products are well known in
Europe and RHEI, through its Pharmacy Division, seeks to firmly
establish the brand in Asia," said Joos Horsten, Executive Chairman
and Chief Executive Officer of RHEI. "The Company's flagship scar
treatment product, in particular, will benefit from RHEI's expertise
marketing to medical professionals such as dermatologists and plastic
surgery clinics. We are pleased to include this line of products
within our Pharmacy Division and we look forward to building market
awareness and acceptance through a strategy that includes outreach to
medical professionals, as well as retail outlets such as pharmacies
and spas."

Drs. Hans Schreuder Vision for Health Skin Care line includes
seven products that give the skin the very best natural and healthy
nutrition. The products contain skin-inherent substances like natural
vitamin E and nutritional ingredients from nature itself, such as
oatmeal, yeast and hamamelis extracts, soya, rice, natural vitamins
and natural lactic acid. These ingredients can solve problems and
restore the skin's natural balance. The product line includes a scar
treatment cream, smoothing morning and night creams to prevent signs
of aging, a facial cleansing lotion and a refreshing cream for legs.
This complete range of products is just the beginning of a new kind
of skin care, making use of homeopathic and phytotherapeutic
principles to stimulate the skin's natural action.

"Professional skin care is one of the fastest-growing segments
within the cosmetics and toiletries industry in China. With an
increase in Chinese living standards, people are seeking more
specialized products and appreciate a holistic approach to
healthcare," said Dr. Hans Schreuder, President and Founder of Drs
Hans Schreuder Products BV. "Our Vision for Health Skin Care line is
a natural way to nourish the skin. RHEI has the experience and
expertise to bring this novel line of skin care products to Asia
where there is a growing desire for naturally-derived products."

About Drs. Hans Schreuder Products BV

Drs. Hans Schreuder Products BV is a successful private company
that specializes in the development and marketing of natural
problem-solving skin care products and other health-related products.
Dr Hans Schreuder, an all-round and versatile organic chemist, is
responsible for product development at Schreuder Research BV. Irene
Schreuder-Tjoa is in charge of management and marketing. The head
office (R&D, Marketing and Sales) is located in Vreeland, the
Netherlands. At the end of 2004, Drs. Hans Schreuder Products BV
launched a newly developed product range under the name 'Drs. Hans
Schreuder, Vision for Health', natural nutrition for the skin.

About RHEI Pharmaceuticals

RHEI Pharmaceuticals is a venture backed specialty pharmaceutical
company with operations in Belgium, the U.S. and in China that
acquires, licenses, develops and commercializes in China proprietary
drug therapies based upon the unmet needs of the emerging China
pharmaceuticals market. RHEI leverages its proprietary and extensive
network of experienced clinical development and regulatory
professionals in China to expedite approvals for pharmaceuticals new
to the China market. RHEI's growing sales and marketing capabilities
then provide broad patient access in China to these new and
critically necessary therapeutics. RHEI applies its unique offering
to branded pharmaceuticals, through its Ethical Division, and to
consumer healthcare and OTC/natural supplement products through its
Pharmacy Division.

Web site: http://www.rheipharma.com

ots Originaltext: RHEI Pharmaceuticals, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Dr. Hans Schreuder, President, or Irene Schreuder-Tjoa, CEO, of Drs.
Hans Schreuder Products BV, +31-294-237-981,
info@drshansschreuder.com; or Scott B. Kozak, Vice President,
Licensing & Corporate Development of RHEI Pharmaceuticals,
+1-203-809-4286; or Eric Goldman, media, +1-917-322-2563, or Rhonda
Chiger, investors, +1-917-322-2569, both of Rx Communications Group,
LLC for RHEI Pharmaceuticals


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

121098

weitere Artikel:
  • Wattner SunAsset 1 startet - Sonnige Aussichten mit neuartigem Fondskonzept Köln (ots) - Das Emissionshaus Wattner Kapital AG kommt mit seinem aktuellen Produkt an den Markt: Der geschlossene Solarfonds Wattner SunAsset 1 investiert in baureife Standorte, lässt Solarkraftwerke darauf errichten und veräußert die produzierenden Kraftwerke anschließend an Investoren. Das Fondsvolumen beträgt 5 Millionen Euro. Die Mindestbeteiligung am Wattner SunAsset 1 liegt bei 5.000 Euro. Bei nur sechs Jahren Laufzeit ist eine Zielrendite (IRR nach Steuern) von 10,5 Prozent angestrebt. Beginnend 2009 ist eine Gesamtausschüttung mehr...

  • euro adhoc: REpower Systems AG / Sonstiges / REpower und RWE Innogy vereinbaren die Verhandlung von Rahmenverträgen über bis zu 1.900 MW -------------------------------------------------------------------------------- Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Verträge 21.02.2008 Hamburg/Essen, 21. Februar 2008. Die REpower Systems Gruppe (WKN 617703) und die auf den Bereich Erneuerbare Energien spezialisierte Tochtergesellschaft des RWE-Konzerns, RWE Innogy, haben heute ein Memorandum of Understanding mehr...

  • euro adhoc: REpower Systems AG / other / REpower and RWE Innogy agree on negotiations for framework agreements for up to 1,900 megawatts -------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- Contracts 21.02.2008 Hamburg/Essen, 21 February 2008. Today, the REpower Systems Group (WKN 617703) and RWE Innogy, the RWE Group´s subsidiary specialising in renewable energies, have signed a Memorandum of Understanding (MoU), which provides for the negotiation mehr...

  • REpower und RWE Innogy vereinbaren die Verhandlung von Rahmenverträgen über bis zu 1.900 MW -------------------------------------------------------------------------------- ots.CorporateNews übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt der Mitteilung ist das Unternehmen verantwortlich. -------------------------------------------------------------------------------- Unternehmen/Verträge Hamburg (euro adhoc) - Hamburg/Essen, 21. Februar 2008. Die REpower Systems Gruppe (WKN 617703) und die auf den Bereich Erneuerbare Energien spezialisierte Tochtergesellschaft des RWE-Konzerns, RWE mehr...

  • REpower and RWE Innogy agree on negotiations for framework agreements for up to 1,900 megawatts -------------------------------------------------------------------------------- ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- companies/contracts Hamburg (euro adhoc) - Hamburg/Essen, 21 February 2008. Today, the REpower Systems Group (WKN 617703) and RWE Innogy, the RWE Group´s subsidiary specialising in renewable energies, have signed a Memorandum of Understanding (MoU), which provides for mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht